Symptoms alone, or low numbers alone, may not justify intervention
doi: 10.3389/fendo.2025.1586589 Received 03 March 2025 Accepted 29 April 2025 Published 21 May 2025 Volume 16 - 2025 Edited by Giacomina Brunetti, University of Bari Aldo Moro, Italy Reviewed by Nagesha Guthalu Kondegowda, City of Hope, United States Nikita Nirwan, Jamia Hamdard University, India Updates Copyright 2025 Chen, Lyu, Zhao, Han, Huang, Yang and Zhou
Key growth drivers included heart failure drug Entresto (sacubitril/valsartan), which will nevertheless face loss of exclusivity in the US this year
Look for positive customer reviews, endorsements from healthcare professionals, and certifications from regulatory bodies
Common side effects include gastrointestinal issues, which lead to about 10% of patients discontinuing use, as well as risks like hypotension, pancreatitis, and the progression of diabetic retinopathy
This is why oral formulations are such a focus area for the leaders in the pack, Novo and Lilly, as well as newer entrants like Kailera, Metsera, and Verdiva
